Login / Signup

Cost per responder analysis of guselkumab versus targeted therapies in the treatment of moderate to severe plaque psoriasis in Germany.

Matthias AugustinDaniel WirthJoerg MahlichAlicia N PepperCheryl Druchok
Published in: The Journal of dermatological treatment (2020)
Guselkumab is a cost-effective therapy option in Germany.
Keyphrases
  • coronary artery disease
  • early onset
  • high intensity
  • combination therapy
  • bone marrow
  • replacement therapy
  • drug induced